logo Hematology/Oncology Research Studies: Open for Enrollment Date: 09/04/19


H3.3.K27M specific peptide vaccine combined with poly-ILCL for the treatment of newly diagnosed HLA-A2+ H3.3K27M positive diffuse intrinsic pontine glioma and other newly diagnosed HLA-A2+ H3.3K27M positive gliomas

NCT#/Phase: NCT02960230
Phase 1
IRB#: 2017-114
Description: This non-randomized study will assess the safety of repeated administration of the H3.3K27M specific vaccine in HLA-A2+ children and young adults with H3.3K27M DIPGs and other gliomas.
Inclusion: Individuals who are between 3 - 21 years of age with newly diagnosed DIPG or other glioma who are positive for H3.3K27M mutation and underwent standard radiation therapy.
Enrollment Status: Open for enrollment
Sponsor: Pacific Pediatric Neuro-Oncology Consortium (PNOC)
Principal Investigator(s): Tabitha Cooney, MD
Contact(s): Tabitha Cooney, MD (510-428-3885 x3398)

Study Link: https://clinicaltrials.gov/ct2/show/NCT02960230

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000